VBI Vaccines Presents Update and New Data Supporting its Glioblastoma...
CAMBRIDGE, Mass., Nov. 20, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") today presented an update and new data supporting its glioblastoma multiforme ("Glioblastoma" or "GBM")...
View ArticleAduro Biotech Europe's Chief Scientific Officer, Andrea Van Elsas, Ph.D....
(Source: Aduro BioTech Inc) (Thomson Reuters ONE via COMTEX) --BERKELEY, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a clinical-stage immunotherapy company, today...
View ArticleBioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two...
(Source: BioLineRX Ltd) Efficacy and safety study, in collaboration with MD Anderson Cancer Center, will assess BL-8040 as combination treatment with immunosuppressants Interim results of study, in...
View ArticleDarzalex: FDA Approved Human Anti-CD38 Monoclonal Antibody for MM
(Continued from Prior Part) Darzalex Johnson & Johnson’s (JNJ) Darzalex (daratumumab) is the first anti-CD38 monoclonal antibody to be approved by the US Food and Drug Administration for multiple...
View ArticleSeattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A...
(Source: Seattle Genetics Inc) -Trial Based on Anti-Leukemic Activity Observed in Ongoing Phase 1 Clinical Trials Evaluating SGN-CD33A in AML- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 23, 2015-- Seattle...
View ArticleOxis Biotech - University of Minnesota Masonic Cancer Center Receive FDA...
TAMPA, Fla., Nov. 23, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today its collaborators at...
View ArticleXencor to Present at Two Upcoming Conferences in December
MONROVIA, Calif., Nov. 24, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Receives Milestone Payment from Merck for Initiation of Phase 1...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about XNCR MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc....
View ArticleXencor Appoints A. Bruce Montgomery, M.D. to Board of Directors
MONROVIA, Calif., March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleHTML PDF (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
(Source: Xencor Inc) MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor to Host R&D Day and Webcast on June 26, 2015
MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor's XmAb5871 Enters Phase 2a Study for Autoimmune Disease
MONROVIA, Calif., Oct. 1, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients...
View ArticleXencor Initiates Phase 1 Study of XmAb7195 for Asthma (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and...
(Source: Xencor Inc) Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) Ongoing Phase 1b/2a clinical trial on track to report topline results by end of 2014 Conference call...
View ArticleXencor Initiates Phase 1 Study of XmAb7195 for Asthma
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about XNCR MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ:...
View ArticleXencor Reports Fourth Quarter and Full Year 2013 Financial Results
MONROVIA, Calif., March 19, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and...
MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View Article